Is This the Right Time to Hold EW Stock in Your Portfolio?Zacks Investment Research · 3 days ago
FDA Approval of Edwards Lifesciences' PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve DiseaseBusiness Wire · 4 days ago
Is EW Overvalued? DCF Says Worth $40GuruFocus · 4 days ago
Edwards Lifesciences Corporation $EW Stock: Birch Hill Investment Advisors LLC Trims PositionDefense World · Oct 18, 2026
First Citizens Bank & Trust Co. Makes New $792,000 Investment in Edwards Lifesciences Corporation $EWDefense World · Oct 17, 2026
Edwards Lifesciences Corporation $EW Stock: Assenagon Asset Management S.A. Boosts StakeDefense World · Oct 16, 2026Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 23, 2026 | $0.74 | $0.78 | Beat |
| Apr 23, 2026 | $0.73 | $0.78 | Beat |
| Feb 10, 2026 | $0.62 | $0.58 | Miss |
| Oct 30, 2025 | $0.60 | $0.67 | Beat |
| Jul 24, 2025 | $0.62 | $0.67 | Beat |
| Apr 23, 2025 | $0.60 | $0.64 | Beat |